Medacta Group SA
2022 Full Year Unaudited Top-Line Figures release / Today's call at 4:00pm CET
Medacta Group SA / Key word(s): Annual Results Press Release – Ad-hoc announcement pursuant to Art. 53 LR |
Medacta Group SA reports a robust 20.4% revenue growth in 2022 reaching 437.1 M€
- FY 2022 revenue amount to Euro 437.1 million, equal to 20.4% growth at reported currency, or 15.0% growth at constant currency1 vs FY 2021
- Significant customer acquisition, salesforce expansion, and successful product introduction
- Positive contribution from all business lines and geographies, despite pandemic restrictions and hospital staffing shortages in some key markets
- True growth beyond mere recovery, with revenue in constant currency up by 36.9% vs FY 2019
- 196 new jobs created, including significant salesforce expansion surpassing 1500 employees at Group level
CASTEL SAN PIETRO, Switzerland, 3 February 2023 – Medacta Group SA (“Medacta”, SIX:MOVE) announces today the Full Year 2022 preliminary unaudited revenue.
Francesco Siccardi, CEO of Medacta, commented: “In 2022 we had once again a year of robust growth and I am very pleased with the achievement of our challenging target. We made strategic investments in strengthening our supply chain by increasing surgical instrument sets and implant stock to serve new customers and to cope with possible shortages, all around the world. The expansion of our salesforce continued across all geographies and business lines, supported by our Marketing and Medical Education Programs.
In a period still characterized by geopolitical tensions and volatile economic conditions, we remain focused on growth and long-term value creation through innovation and sustainability. I am grateful to all our Employees for their commitment and outstanding performance, and I also extend our thanks to our valued Customers and Suppliers for their partnership during these challenging times.”